With 1.2 million patients, type 2 diabetes is the most common chronic and lifestyle related disease in The Netherlands. Annual healthcare costs are E2400pp, mounting to >2.5 billion euro. Various long-term studies have shown up to 40% remission and further reversal but by their nature were research projects, depending on research funding and thus finalized upon ending funds. This project will comprise 36 months but will be open ended as all aspects will become socio-economically sustainable.
DDRS will enrol and sustain 1000 type 2 diabetes (T2D) patients in the Schilderswijk and Bouwlust-Vrederust Neighbourhoods of Den Haag and aim to achieve remission or reversal by a personalized medical, biological, and behavioural intervention. Societal, infrastructural, data and economical aspects will be accomplished in parallel projects. The economic value-for-money will be quantified. 1000 comparable T2D-patients in neighbouring Quarters will serve as usual care controls.
Intervention and diagnosis will be fine-tuned to individual needs and preferences.
Onboarding will be done by a “360O diagnosis” between professional and patient. Partcipants will undergo a “phenotypic flexibility” assay, quantifying relative contributions of liver and muscle insulin resistance and beta cell insulin secretion.
A series of short term continuous glucose qualifications will aid in the biological and behavioral aspects of diabetes remission. The (epi-)genetics of type 2 diabetes will be examined in the complete (intervention and control) study population.
This will be a long-lasting and large lifestyle based diabetes remission study, convincing healthcare insurance and government to invest in a less costly and more convenient lifestyle related diabetes treatment, and accelerate new businesses and business models focusing on aspects of lifestyle.